+

WO1999022763A3 - Immunomodulateurs encapsules utilises comme adjuvants de vaccins - Google Patents

Immunomodulateurs encapsules utilises comme adjuvants de vaccins Download PDF

Info

Publication number
WO1999022763A3
WO1999022763A3 PCT/US1998/023313 US9823313W WO9922763A3 WO 1999022763 A3 WO1999022763 A3 WO 1999022763A3 US 9823313 W US9823313 W US 9823313W WO 9922763 A3 WO9922763 A3 WO 9922763A3
Authority
WO
WIPO (PCT)
Prior art keywords
encapsulated
immunomodulator
vaccine adjuvants
useful
adjuvant
Prior art date
Application number
PCT/US1998/023313
Other languages
English (en)
Other versions
WO1999022763A2 (fr
Inventor
Richard S Dondero
Bruce C Galton
Leslie S Casey
Original Assignee
Cistron Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cistron Biotechnology Inc filed Critical Cistron Biotechnology Inc
Priority to IL13548098A priority Critical patent/IL135480A0/xx
Priority to EP98955231A priority patent/EP1027071A2/fr
Priority to AU12084/99A priority patent/AU1208499A/en
Priority to JP2000518694A priority patent/JP2001521908A/ja
Priority to CA002307541A priority patent/CA2307541A1/fr
Publication of WO1999022763A2 publication Critical patent/WO1999022763A2/fr
Publication of WO1999022763A3 publication Critical patent/WO1999022763A3/fr
Priority to AU2003200723A priority patent/AU2003200723B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des compositions comprenant un immunomodulateur encapsulé, tel que des cytokines et des lymphokines, qui est utilisé comme adjuvant pour stimuler une réponse immunitaire lorsqu'il est administré à un être humain ou à un animal. Par exemple, une lymphokine telle que l'IL-1α ou l'IL-1β peut être utilisée comme immunomodulateur encapsulé dans une matrice de la présente invention. La composition encapsulée peut comprendre un antigène de vaccin, tel qu'un virus entier inactivé ou atténué, des peptides recombinés ou synthétiques et d'autres matériaux antigéniques. La matrice d'encapsulation peut être naturelle ou synthétique. La présente invention concerne également l'utilisation, chez un être humain ou un animal, d'un immunomodulateur encapsulé comme adjuvant dans le but de stimuler les réponses immunitaires à un antigène ou à un autre matériau envers lequel on désire provoquer une réponse immunitaire.
PCT/US1998/023313 1997-10-31 1998-11-02 Immunomodulateurs encapsules utilises comme adjuvants de vaccins WO1999022763A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
IL13548098A IL135480A0 (en) 1997-10-31 1998-11-02 Encapsulated immunomodulators useful as vaccine adjuvants
EP98955231A EP1027071A2 (fr) 1997-10-31 1998-11-02 Immunomodulateurs encapsules utilises comme adjuvants de vaccins
AU12084/99A AU1208499A (en) 1997-10-31 1998-11-02 Encapsulated immunomodulators useful as vaccine adjuvants
JP2000518694A JP2001521908A (ja) 1997-10-31 1998-11-02 ワクチンアジュバントとして有用な封入された免疫調節物質
CA002307541A CA2307541A1 (fr) 1997-10-31 1998-11-02 Immunomodulateurs encapsules utilises comme adjuvants de vaccins
AU2003200723A AU2003200723B2 (en) 1997-10-31 2003-02-28 Encapsulated immunomodulators useful as vaccine adjuvants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96240797A 1997-10-31 1997-10-31
US08/962,407 1997-10-31

Publications (2)

Publication Number Publication Date
WO1999022763A2 WO1999022763A2 (fr) 1999-05-14
WO1999022763A3 true WO1999022763A3 (fr) 1999-08-05

Family

ID=25505819

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/023313 WO1999022763A2 (fr) 1997-10-31 1998-11-02 Immunomodulateurs encapsules utilises comme adjuvants de vaccins

Country Status (6)

Country Link
EP (1) EP1027071A2 (fr)
JP (1) JP2001521908A (fr)
AU (1) AU1208499A (fr)
CA (1) CA2307541A1 (fr)
IL (1) IL135480A0 (fr)
WO (1) WO1999022763A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960744A (zh) * 2004-02-27 2007-05-09 瓦克斯咨询公司 肽IL1β和TNFα以及应用其治疗的方法
US20090068254A1 (en) 2005-09-30 2009-03-12 Lipoxen Technologies Limited Multivalent liposomal vaccine compositions comprising polysaccharide antigens and a protein adjuvant
EP3067048B1 (fr) * 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions d'induction des réponses immunitaires

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03170498A (ja) * 1989-11-29 1991-07-24 Teikoku Hormone Mfg Co Ltd ペプチドおよびこのペプチドを含有する薬剤
WO1997049423A2 (fr) * 1996-06-24 1997-12-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Composition de vaccin contre la grippe encapsulee dans des liposomes et leur procede de fabrication

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0604727A1 (fr) * 1992-12-31 1994-07-06 American Cyanamid Company Immunogénéité améliorée d'un vaccin par incorporation d'un cytocine dans un complexe immunostimulant contenant un antigène

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03170498A (ja) * 1989-11-29 1991-07-24 Teikoku Hormone Mfg Co Ltd ペプチドおよびこのペプチドを含有する薬剤
WO1997049423A2 (fr) * 1996-06-24 1997-12-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Composition de vaccin contre la grippe encapsulee dans des liposomes et leur procede de fabrication

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 9136, Derwent World Patents Index; Class B04, AN 91-262316, XP002104336 *
LIMOR C ET AL: "Characterization of PLGA microspheres for the controlled delivery of IL-1alpha for tumor immunotherapy", JOURNAL OF CONTROLLED RELEASE, vol. 43, no. 2-3, 18 January 1997 (1997-01-18), pages 261-272, XP004069894 *

Also Published As

Publication number Publication date
IL135480A0 (en) 2001-05-20
JP2001521908A (ja) 2001-11-13
WO1999022763A2 (fr) 1999-05-14
EP1027071A2 (fr) 2000-08-16
CA2307541A1 (fr) 1999-05-14
AU1208499A (en) 1999-05-24

Similar Documents

Publication Publication Date Title
WO2001039803A3 (fr) Muteines de l'interleukine 1 utiles comme adjuvants de vaccins
FR2686896B1 (fr) Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique.
ATE229978T1 (de) Helicobacter proteine und impstoffe
CA2143823A1 (fr) Analogues synthetiques de peptides, modifies pour la reversion, l'inversion et la reversion-inversion
PT1090033E (pt) Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
WO2001095919A3 (fr) Virus recombinant non replicant exprimant gm-csf et utilisation de celui-ci pour ameliorer des reponses immunitaires
NZ331651A (en) BSW17 peptide immunogens for vaccination against and treatment of allergy
DE69943170D1 (de) Immunologische Zusammensetzung und Impfstoffe, die einen auf N-Formyl-Methionyl Peptide bestehenden Adjuvans enthalten
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
EP1611897A3 (fr) Cellules entières ou lysées d'insecte utilisées comme adjuvants d'antigènes
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
FI920132A0 (fi) Stabila vaccinkompositioner innehaollande interleukiner.
NZ309659A (en) Composition comprising LbeIF4A and/or LmeIF4A polypeptides (Leishmania antigen) and methods for enhancing immune responses
WO2003007869A3 (fr) Compositions immunogenes contenant des antigenes, des vecteurs geniques et des microspheres biodegradables chargees d'adjuvants
DE69919984D1 (de) Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe
ATE287957T1 (de) Peptide abgeleitet vom bindungs (g) protein des respiratorisches synzytialvirus
WO2015138471A1 (fr) Poxvirus inactivé par la chaleur améliorant les résultats de vaccination
DE69836744D1 (de) Gruppe a streptokokken-impfstoff
WO1999022763A3 (fr) Immunomodulateurs encapsules utilises comme adjuvants de vaccins
WO2002034287A3 (fr) Nouvelles formulations de vaccin therapeutique
EP0236977A3 (fr) Vaccins contre la diarrhée bovine virale et le choléra porcin
TW200504216A (en) Immunization of fish with plant-expressed recombinant proteins
WO2000006198A3 (fr) Adjuvant comprenant un tensioactif pulmonaire
SE9604296D0 (sv) New pharmaceutical formulation of polypeptides
HK1025220A1 (en) Novel saponin compositions and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 135480

Country of ref document: IL

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA IL JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA IL JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1998955231

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2307541

Country of ref document: CA

Ref country code: CA

Ref document number: 2307541

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 518694

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 12084/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998955231

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998955231

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载